Tagged with LatAm

LatAm Back in Latin America after several years in the US and Europe, Teva LatAm Head and Mexico GM Rodrigo Fernandez explains how the affiliate has adapted its strategy across the region and delivered consistent growth in most of its LatAm markets. He also explains how the region is confronting some…

Americas Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth and plans to launch 14 new products there by 2025, most importantly its European Medicines Agency-approved dengue vaccine. She also…

Mexico Mexico, with the second largest pharmaceutical market in Latin America, has a number of strong local pharma industry players. These companies, no longer focused solely on the domestic market, are extending their footprint into LatAm. Grupo Sanfer/Hormona Mexico has already taken up positions across the region.   Laboratorios Sanfer, founded…

Mexico María del Socorro España Lomelí, the executive director of Mexico’s National Association of Manufacturers of Medicines (ANAFAM), speaks to PharmaBoardroom about ANAFAM’s evolving relationship with the Mexican government and the changes in the country’s procurement law, which gave rise to widespread procurement issues. She also discusses ANAFAM member companies’ internationalisation…

Americas In 2019 the pharma industry financed some 700 clinical studies in Latin America with investments of more than USD one billion and according to FIFARMA, the leading association of innovators in the region, LatAm currently supports about 10 percent of the world’s clinical research. Local industry leaders discuss the advantages…

Mexico Dagoberto Cortés Cervantes, president of Mexico’s National Association of Medicines Manufacturers (ANAFAM) and director of Grupo Sanfer/Hormona Mexico, outlines the expansion strategy that has led the manufacturing group to extend its presence beyond Mexico into the broader LatAm region and the importance of the “Alianza del Pacifico”  trade agreement linking…

LatAm A breakdown of the investments made by the pharmaceutical industry in clinical studies across the Latin American region. According to the US National Library of Medicine’s ClinicalTrials.gov, USD 1.1 billion were invested in 2019 with Mexico, Brazil and Argentina at the head of the LatAm countries where these investments were…

LatAm Yaneth Giha of FIFARMA – the leading association for the innovative pharmaceutical industry in Latin America – gives a bird’s-eye overview on some of the key trends in LatAm healthcare, from regulatory and access challenges to the impact of the COVID-19 pandemic, the region’s potential as a clinical trials hub,…

LatAm Florencia Davel, head of LatAm operations for Bristol Myers Squibb (BMS) looks back on a successful four years in position, shaping the regional organisation into a true biopharma player in line with a global strategy shift. Davel also casts her eye over the market access scenario in LatAm, why BMS…

LatAm As selected by the Generics & Biosimilars Initiative (GABI), these are the top ten pharma companies ranked by turnover in Argentina, Brazil, Chile, Colombia, and Mexico for 2021. As the chart shows, the Argentinian and Brazilian Top Tens are dominated by domestic companies, while multinationals hold sway in Colombia and…

Mexico The Mexican Association of Pharmaceutical Research Industries (AMIIF) represents the innovative pharmaceutical industry in Mexico, advocating for innovation and promoting dialogue with local authorities. AMIIF’s Executive Director, Cristobal Thompson, discusses the country and the organization’s response to the COVID-19 pandemic and outlines Mexico’s healthcare challenges and how they have evolved…

Brazil Renata Mihich, a 25-year DHL veteran, recently took on a new role as Head of LatAm for Italian healthcare logistics specialist BOMI GROUP. At a moment of career transformation, BOMI GROUP is also on the verge of a big change with UPS Healthcare acquiring the company earlier this year. Mihich…